Developer docs
API playgroundTry for free, no card

Search company profiles

Apobiologix

Full company profile

uuid000ernk

Namestring
Apobiologix
Legal namestring
Apotex Inc.
Websiteurl
apobiologix.com
Company typeenum
Private
Founded yearint
2007
Descriptiontext

Apobiologix is a specialty pharmaceutical division of Apotex Inc., headquartered in Toronto, Canada, focused on developing and commercializing biosimilar medicines for the Canadian market. Its portfolio comprises three marketed oncology biosimilars — Bambevi and Grastofil (filgrastim biosimilars) and Lapelga (pegfilgrastim biosimilar) — used for prevention and treatment of chemotherapy-induced neutropenia. Apobiologix develops these products in partnership with Apotex's broader manufacturing infrastructure, leveraging Health Canada-approved biosimilar regulatory pathways and a commercial approach centered on HCP engagement, formulary listing, and patient support.

The company monetizes through product sales to Canadian hospital and institutional pharmacies, community pharmacies, and ultimately reimbursed by provincial/territorial public drug plans and private insurers. Its go-to-market combines a traditional field-sales model targeting oncologists and oncology pharmacists with a multi-channel stakeholder engagement program — the Apobiologix Partnership Program (APP) — that includes educational fellowships (ASH/ASCO sponsorships), the ABC Program, HOPE Awards, and the Quebec Oncology Pharmacist Partnership Program. Direct patient access is facilitated through the ANSWERS patient support program (with ANSWERS Select for copay support), which has supported more than 30,000 patients since 2016 and provides injection training for Lapelga's pre-filled syringe and autoinjector formats.

Apobiologix positions itself as a pioneer and leader in oncology biosimilars in Canada, building on Apotex's 40+ year domestic pharmaceutical heritage. It maintains a stated pipeline of additional biosimilars targeting new therapeutic areas beyond oncology supportive care. Operationally the unit is supported by a leadership team spanning medical affairs, market access, sales, marketing, and operations, with explicit responsibility for biosimilar commercialization strategy and pan-Canadian reimbursement engagement, including participation in the Biosimilars Market Access Committee.

Short descriptiontext

Apobiologix is a Toronto-based specialty pharmaceutical division of Apotex Inc. that develops and commercializes biosimilar oncology supportive-care medicines (filgrastim and pegfilgrastim) for Canadian patients, healthcare providers, and public drug plans.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersToronto, Canada
HQ citystring
Toronto
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
oncology biosimilars, biosimilar pharmaceuticals, patient support programs, biologic medicines, pharmaceutical commercialization
Industry2 codes
PRIMARYHLAIAFAA
Monoclonal Antibody (mAb) Biosimilars
SECONDARYHLAIAJAH
Biologics & Biosimilars Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Oncology Biosimilars
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Biosimilar Product Sales
TypeOne Time License
Description

Apobiologix generates revenue through the sale of marketed biosimilar products including Bambevi (filgrastim biosimilar), Grastofil (filgrastim biosimilar), and Lapelga (pegfilgrastim biosimilar). These products are sold to healthcare providers, hospitals, and through pharmacies in Canada. Revenue comes from product sales to the Canadian healthcare system including public drug plans and private insurers.

apobiologix.com
2Pipeline Product Development
TypeSubscription Recurring
Description

The company continues investing in a pipeline of additional biosimilars in oncology and expanding to new therapeutic areas, suggesting future revenue streams from new product launches.

apobiologix.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Supply Chain, Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1ANSWERS
Description

Comprehensive patient support program dedicated to helping Canadian patients prescribed an Apobiologix product gain access to their medication.

apobiologix.com
+4 more records
Core offering1 text field

Apobiologix is a division of Apotex Inc. that develops, manufactures, and commercializes biosimilar versions of oncology biologic medicines in Canada. Its marketed portfolio consists of three products — Bambevi and Grastofil (filgrastim biosimilars) and Lapelga (pegfilgrastim biosimilar) — used for the prevention and treatment of chemotherapy-induced neutropenia. The company complements the products with patient and healthcare-provider support programs (ANSWERS and the Apobiologix Partnership Program).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 30,000+ patients supported since 2016 through ANSWERS patient support program
+2 more records
Product overview1 text field

Apobiologix is a division of Apotex Inc. focused on the commercialization of biosimilars in Canada. The company operates as a pioneer and leader in oncology biosimilars, offering a portfolio of three marketed products: Bambevi, Grastofil (filgrastim), and Lapelga (pegfilgrastim). These biosimilar products provide affordable supportive care therapies for cancer patients undergoing chemotherapy, addressing neutropenia management. Apobiologix also maintains a pipeline of additional biosimilars and has a patient support program called ANSWERS, an HCP support program, and the Apobiologix Partnership Program (APP) for stakeholder engagement.

Product and service3 records
1Bambevi (biosimilar)
CategoryOncology biosimilars
Description

Bambevi is an Apobiologix-marketed biosimilar product intended for supportive care in oncology patients; product monograph and patient medication information are published.

2Grastofil (filgrastim biosimilar)
CategoryOncology biosimilars
Description

Grastofil is a filgrastim biosimilar used for the prevention and treatment of neutropenia in cancer patients undergoing chemotherapy, administered via pre-filled syringe.

3Lapelga (pegfilgrastim biosimilar)
CategoryOncology biosimilars
Description

Lapelga is a pegfilgrastim biosimilar for reducing the incidence of febrile neutropenia in patients treated with chemotherapy, available as a pre-filled syringe and a pre-filled autoinjector.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-08-01
Description

In August 2025, Intas Pharmaceuticals partnered with Accord Healthcare to acquire the Udenyca product line from Coherus Biosciences, forming one of the world's largest pegfilgrastim suppliers. This is noted as market context for the filgrastim biosimilars market in which Apobiologix operates with its Lapelga product.

2Healthcare Provider Partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Apobiologix works in cooperation with healthcare provider partners to enhance patient access, optimize patient care, and ensure sustainability of the Canadian healthcare system. This includes pharmacists, physicians, and oncology specialists who prescribe and manage biosimilar therapies.

apobiologix.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Apobiologix supports the IMD Health Education Program as part of the APP's Educational Patient Resources pillar. IMD Health provides patient education resources to support the disease journey for patients.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Amgen is both the originator of reference biologics in the G-CSF space (Neupogen, Neulasta) and a developer of biosimilars. Apobiologix competes against Amgen's originator franchise while operating in the biosimilar space, and Amgen's leadership team (SVP Mike Woolcock) previously held roles at Amgen.

TypeDirect peer
Description

Coherus is a focused biosimilar developer and commercializer with Udenyca (pegfilgrastim biosimilar) as a flagship product directly competitive with Lapelga. Coherus is a closely comparable pure-play biosimilar commercialization company, though larger in geographic scope.

TypeBroad incumbent
Description

Viatris (Mylan/Upjohn combination) markets biosimilars including a portfolio that competes in oncology supportive care. They are a broad incumbent with global commercial reach including Canada, and a comparable generics-plus-biosimilars commercial model.

TypeDirect peer
Description

Samsung Bioepis is a leading dedicated biosimilar developer with multiple approved products across oncology, immunology, and ophthalmology. They compete with Apobiologix in the G-CSF class and represent a focused biosimilar pure-play comparable in business model.

TypeDirect peer
Description

Celltrion is a South Korean biosimilar-focused manufacturer with a portfolio including oncology supportive care biosimilars. As a pure-play biosimilar developer-commercializer, Celltrion is highly comparable in business model to Apobiologix, though at a much larger global scale.

6Sandoz
TypeBroad incumbent
Description

Sandoz is the global market leader in biosimilars, with a broad oncology biosimilar portfolio including filgrastim/pegfilgrastim (Zarxio, Ziextenzo) and many other molecules. It competes directly with Apobiologix's Grastofil and Lapelga in the same therapeutic class, but operates at vastly greater geographic scale.

TypeBroad incumbent
Description

Pfizer (post-Hospira integration) markets multiple biosimilars including Nivestym (filgrastim biosimilar) directly competitive with Apobiologix's Grastofil. As a broad incumbent pharmaceutical major, Pfizer has global scale advantages in manufacturing and commercialization.

TypeEmerging player
Description

Biocon Biologics is a global biosimilar developer with oncology and immunology biosimilars marketed in developed markets. As a focused biosimilar player with global ambitions, Biocon is comparable in business model to Apobiologix but operates at a larger international scale.

TypeBroad incumbent
Description

Teva markets biosimilars including oncology supportive care products and has a presence in Canada. As a broad pharmaceutical incumbent with both generics and biosimilars, Teva overlaps with Apobiologix's commercial model in the Canadian market.

TypeDirect peer
Description

Following the August 2025 acquisition of Coherus' Udenyca pegfilgrastim franchise, Accord/Intas became one of the world's largest pegfilgrastim suppliers. They directly compete with Apobiologix's Lapelga in the G-CSF biosimilar market globally and likely in Canada via distribution.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Apobiologix

Oncology Biosimilarsapobiologix.com

Apobiologix is a Toronto-based specialty pharmaceutical division of Apotex Inc. that develops and commercializes biosimilar oncology supportive-care medicines (filgrastim and pegfilgrastim) for Canadian patients, healthcare providers, and public drug plans.

What Apobiologix does

Apobiologix is a specialty pharmaceutical division of Apotex Inc., headquartered in Toronto, Canada, focused on developing and commercializing biosimilar medicines for the Canadian market. Its portfolio comprises three marketed oncology biosimilars — Bambevi and Grastofil (filgrastim biosimilars) and Lapelga (pegfilgrastim biosimilar) — used for prevention and treatment of chemotherapy-induced neutropenia. Apobiologix develops these products in partnership with Apotex's broader manufacturing infrastructure, leveraging Health Canada-approved biosimilar regulatory pathways and a commercial approach centered on HCP engagement, formulary listing, and patient support.

The company monetizes through product sales to Canadian hospital and institutional pharmacies, community pharmacies, and ultimately reimbursed by provincial/territorial public drug plans and private insurers. Its go-to-market combines a traditional field-sales model targeting oncologists and oncology pharmacists with a multi-channel stakeholder engagement program — the Apobiologix Partnership Program (APP) — that includes educational fellowships (ASH/ASCO sponsorships), the ABC Program, HOPE Awards, and the Quebec Oncology Pharmacist Partnership Program. Direct patient access is facilitated through the ANSWERS patient support program (with ANSWERS Select for copay support), which has supported more than 30,000 patients since 2016 and provides injection training for Lapelga's pre-filled syringe and autoinjector formats.

Apobiologix positions itself as a pioneer and leader in oncology biosimilars in Canada, building on Apotex's 40+ year domestic pharmaceutical heritage. It maintains a stated pipeline of additional biosimilars targeting new therapeutic areas beyond oncology supportive care. Operationally the unit is supported by a leadership team spanning medical affairs, market access, sales, marketing, and operations, with explicit responsibility for biosimilar commercialization strategy and pan-Canadian reimbursement engagement, including participation in the Biosimilars Market Access Committee.

Apobiologix firmographics

Firmographics
Name
Apobiologix
Legal name
Apotex Inc.
Website
https://apobiologix.com
Company type
Private
Founded year
2007
Operating status
Operating
Headcount range
11–50 employees
Short description
Apobiologix is a Toronto-based specialty pharmaceutical division of Apotex Inc. that develops and commercializes biosimilar oncology supportive-care medicines (filgrastim and pegfilgrastim) for Canadian patients, healthcare providers, and public drug plans.
Ownership category
akta.pro rank

Apobiologix industry classification

Industry
Product category
Oncology Biosimilars
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAFAA
Monoclonal Antibody (mAb) Biosimilars
SECONDARYHLAIAJAH
Biologics & Biosimilars Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling

Keywords

  • Oncology biosimilars
  • Biosimilar pharmaceuticals
  • Patient support programs
  • Biologic medicines
  • Pharmaceutical commercialization

Where Apobiologix is headquartered

Location

Headquarters

HQ city
Toronto
HQ country
Canada
HQ region
North America

Offices1 record

Markets served

Apobiologix business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Biosimilar Product Sales: Apobiologix generates revenue through the sale of marketed biosimilar products including Bambevi (filgrastim biosimilar), Grastofil (filgrastim biosimilar), and Lapelga (pegfilgrastim biosimilar). These products are sold to healthcare providers, hospitals, and through pharmacies in Canada. Revenue comes from product sales to the Canadian healthcare system including public drug plans and private insurers.
  2. Pipeline Product Development: The company continues investing in a pipeline of additional biosimilars in oncology and expanding to new therapeutic areas, suggesting future revenue streams from new product launches.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Apobiologix product offering

Product offering

Core offering

Apobiologix is a division of Apotex Inc. that develops, manufactures, and commercializes biosimilar versions of oncology biologic medicines in Canada. Its marketed portfolio consists of three products — Bambevi and Grastofil (filgrastim biosimilars) and Lapelga (pegfilgrastim biosimilar) — used for the prevention and treatment of chemotherapy-induced neutropenia. The company complements the products with patient and healthcare-provider support programs (ANSWERS and the Apobiologix Partnership Program).

Product overview

Apobiologix is a division of Apotex Inc. focused on the commercialization of biosimilars in Canada. The company operates as a pioneer and leader in oncology biosimilars, offering a portfolio of three marketed products: Bambevi, Grastofil (filgrastim), and Lapelga (pegfilgrastim). These biosimilar products provide affordable supportive care therapies for cancer patients undergoing chemotherapy, addressing neutropenia management. Apobiologix also maintains a pipeline of additional biosimilars and has a patient support program called ANSWERS, an HCP support program, and the Apobiologix Partnership Program (APP) for stakeholder engagement.

Differentiator

Problem solved

Functional benefit

Brands

  • ANSWERS: Comprehensive patient support program dedicated to helping Canadian patients prescribed an Apobiologix product gain access to their medication.
  • ANSWERS Select
  • APP (Apobiologix Partnership Program)
  • HOPE Awards
  • ABC Program

Products and services

  • Bambevi (biosimilar) Bambevi is an Apobiologix-marketed biosimilar product intended for supportive care in oncology patients; product monograph and patient medication information are published.
  • Grastofil (filgrastim biosimilar) Grastofil is a filgrastim biosimilar used for the prevention and treatment of neutropenia in cancer patients undergoing chemotherapy, administered via pre-filled syringe.
  • Lapelga (pegfilgrastim biosimilar) Lapelga is a pegfilgrastim biosimilar for reducing the incidence of febrile neutropenia in patients treated with chemotherapy, available as a pre-filled syringe and a pre-filled autoinjector.

Quantifiable outcome

  • 30,000+ patients supported since 2016 through ANSWERS patient support program
  • +2 more outcomes

Companies that use Apobiologix

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Apobiologix technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Apobiologix partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered minor and core.

  • Intas Pharmaceuticals / Accord HealthcareminorStrategic or Co-development Partner · 1 August 2025In August 2025, Intas Pharmaceuticals partnered with Accord Healthcare to acquire the Udenyca product line from Coherus Biosciences, forming one of the world's largest pegfilgrastim suppliers. This is noted as market context for the filgrastim biosimilars market in which Apobiologix operates with its Lapelga product.
  • Healthcare Provider PartnerscoreStrategic or Co-development PartnerApobiologix works in cooperation with healthcare provider partners to enhance patient access, optimize patient care, and ensure sustainability of the Canadian healthcare system. This includes pharmacists, physicians, and oncology specialists who prescribe and manage biosimilar therapies.
  • IMD HealthminorStrategic or Co-development PartnerApobiologix supports the IMD Health Education Program as part of the APP's Educational Patient Resources pillar. IMD Health provides patient education resources to support the disease journey for patients.

Scale indicators4 records

Recent moves6 records

Expansion highlights4 records

Apobiologix competitors and assessment

Company assessment

Broad incumbents

  • Amgen: Amgen is both the originator of reference biologics in the G-CSF space (Neupogen, Neulasta) and a developer of biosimilars. Apobiologix competes against Amgen's originator franchise while operating in the biosimilar space, and Amgen's leadership team (SVP Mike Woolcock) previously held roles at Amgen.
  • Viatris: Viatris (Mylan/Upjohn combination) markets biosimilars including a portfolio that competes in oncology supportive care. They are a broad incumbent with global commercial reach including Canada, and a comparable generics-plus-biosimilars commercial model.
  • Sandoz: Sandoz is the global market leader in biosimilars, with a broad oncology biosimilar portfolio including filgrastim/pegfilgrastim (Zarxio, Ziextenzo) and many other molecules. It competes directly with Apobiologix's Grastofil and Lapelga in the same therapeutic class, but operates at vastly greater geographic scale.
  • Pfizer: Pfizer (post-Hospira integration) markets multiple biosimilars including Nivestym (filgrastim biosimilar) directly competitive with Apobiologix's Grastofil. As a broad incumbent pharmaceutical major, Pfizer has global scale advantages in manufacturing and commercialization.
  • Teva Pharmaceutical Industries: Teva markets biosimilars including oncology supportive care products and has a presence in Canada. As a broad pharmaceutical incumbent with both generics and biosimilars, Teva overlaps with Apobiologix's commercial model in the Canadian market.

Direct peers

  • Coherus BioSciences: Coherus is a focused biosimilar developer and commercializer with Udenyca (pegfilgrastim biosimilar) as a flagship product directly competitive with Lapelga. Coherus is a closely comparable pure-play biosimilar commercialization company, though larger in geographic scope.
  • Samsung Bioepis: Samsung Bioepis is a leading dedicated biosimilar developer with multiple approved products across oncology, immunology, and ophthalmology. They compete with Apobiologix in the G-CSF class and represent a focused biosimilar pure-play comparable in business model.
  • Celltrion: Celltrion is a South Korean biosimilar-focused manufacturer with a portfolio including oncology supportive care biosimilars. As a pure-play biosimilar developer-commercializer, Celltrion is highly comparable in business model to Apobiologix, though at a much larger global scale.
  • Accord Healthcare (Intas Pharmaceuticals): Following the August 2025 acquisition of Coherus' Udenyca pegfilgrastim franchise, Accord/Intas became one of the world's largest pegfilgrastim suppliers. They directly compete with Apobiologix's Lapelga in the G-CSF biosimilar market globally and likely in Canada via distribution.

Emerging players

  • Biocon: Biocon Biologics is a global biosimilar developer with oncology and immunology biosimilars marketed in developed markets. As a focused biosimilar player with global ambitions, Biocon is comparable in business model to Apobiologix but operates at a larger international scale.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Apobiologix social profiles

Digital presence

Apobiologix financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Apobiologix leadership team

Management profile

Number of profiles

Profiles6 records

Apobiologix funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Apobiologix M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Apobiologix

What does Apobiologix do?

Apobiologix is a division of Apotex Inc. that develops, manufactures, and commercializes biosimilar versions of oncology biologic medicines in Canada. Its marketed portfolio consists of three products — Bambevi and Grastofil (filgrastim biosimilars) and Lapelga (pegfilgrastim biosimilar) — used for the prevention and treatment of chemotherapy-induced neutropenia. The company complements the products with patient and healthcare-provider support programs (ANSWERS and the Apobiologix Partnership Program).

Is Apobiologix a public or private company?

Apobiologix is a private company. It is classified as corporate owned and is currently operating.

When was Apobiologix founded?

Apobiologix was founded in 2007. It employs 11 to 50 people.

Where is Apobiologix based?

Apobiologix is headquartered in Toronto, Canada, in the North America region.

How does Apobiologix make money?

Two revenue lines are on record. Biosimilar Product Sales are the primary driver. The others are pipeline Product Development.

Who are Apobiologix's main competitors?

Broad incumbents on record are Amgen, Viatris, Sandoz, Pfizer and Teva Pharmaceutical Industries. Direct peers are Coherus BioSciences, Samsung Bioepis, Celltrion and Accord Healthcare (Intas Pharmaceuticals). Biocon is listed as an emerging player.

Does Apobiologix have an API?

No public API is recorded for Apobiologix.

What industry is Apobiologix in?

Apobiologix's product category is Oncology Biosimilars. Its primary akta.pro industry code is HLAIAFAA, Monoclonal Antibody (mAb) Biosimilars, with a secondary code of HLAIAJAH, Biologics & Biosimilars Distributors. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireApobiologix Applauds Supreme Court Decision in Sandoz Biosimilar CaseApobiologix announced support for the Supreme Court's ruling in Sandoz v Amgen, which allows biosimilar companies to give the 180-day notice to reference product companies before FDA approval. The ruling clarifies that the notice timing is not tied to participation in the patent dance, potentially speeding biosimilar access to patients.PR NewswireMeridian Lab and Apobiologix Enter into a Definitive Agreement for Development of Docetaxel InjectionMeridian Laboratories, a specialty-oncology drug development company based in Buffalo, IL, has entered into a definitive agreement with Apobiologix, a division of the Apotex Inc. group, to develop and market an improved one-vial liquid formulation of docetaxel injection for treating multiple forms of cancer. Under the terms of the agreement, Apobiologix will pay Meridian a combination of milestone payments and royalties, with possibilities for co-development and marketing of additional pipeline products. The announcement follows positive feedback from the U.S. FDA, which agreed to allow the 505(b)(2) regulatory pathway for the NDA submission, potentially reducing development costs and timelines compared to traditional routes.PR NewswireBiologics & Biosimilars Collective Intelligence Consortium (BBCIC) Announces Addition of Apobiologix to ConsortiumThe Biologics & Biosimilars Collective Intelligence Consortium (BBCIC) announced the addition of Apobiologix as a new participating organization in its public health initiative to monitor biosimilars and novel biologics for effectiveness and safety. The BBCIC draws on de-identified medical and pharmacy data covering 100 million people and applies scientific methods similar to the FDA Sentinel initiative for post-market surveillance. Research from the IMS Institute predicts biosimilars could save up to $110 billion in the U.S. healthcare system by 2020.PR NewswireApobiologix Announces Victory Over Amgen in Biosimilar Patent CaseApobiologix achieved a landmark district court victory on September 6, 2016, when Judge Cohn of the Southern District of Florida ruled that the company's manufacturing process for its Grastofil and Lapelga biosimilar products did not infringe Amgen's US Patent No. 8,952,138. This marks the first time a biosimilar applicant proceeding under the Biosimilar Price Competition and Innovation Act has won a district court case. The company has subsequently filed a Petition for Certiorari with the US Supreme Court to challenge the Federal Circuit's requirement that biosimilar applicants wait 180 days after FDA approval before launching products.